Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Here’s How Much $1000 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 21.24% on an annualized basis producing an average annual return of 27.82%. Currently, Regeneron Pharmaceuticals has a market capitalization of $81.63 billion.
If You Invested $100 In This Stock 20 Years Ago, You Would Have $5,000 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 14.25% on an annualized basis producing an average annual return of 21.62%. Currently, Regeneron Pharmaceuticals has a market capitalization of $80.23 billion.
Regeneron Pharmaceuticals Announces Libtayo Receives Positive CHMP Opinion Recommending Approval To Treat Advanced Cervical Cancer
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for
Sanofi – Regeneron Tout Additional Positive Data From Flagship Dupixent Product
Sanofi SA (NASDAQ:SNY) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) presented more positive data for their Dupixent product. The companies said new Dupixent data showed…
Regeneron and Sanofi Announced Dupixent Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis in Children 1 to 11
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented late-breaking positive results from a Phase 3 trial evaluating the investigational use of Dupixent® (dupilumab) in children aged 1 to 11 years with active eosinophilic esophagitis (EoE).